Controversies regarding tamoxifen and uterine carcinoma.
An increasing number of cases of endometrial cancer in women receiving tamoxifen have been reported but most are from non-randomized studies and case reports. In the last year, there have been no further results either confirming or disproving an association between tamoxifen and endometrial cancer from randomized controlled studies in breast cancer patients and those participating in chemopreventative trials with tamoxifen. Several papers have examined the possible mechanisms behind tamoxifen's endometrial effects.
Neven
P
P
Algemene Kliniek St.-Jan, Department of Obstetrics and Gynaecology, Brussels, Belgium.
Vergote
I
I
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D016889:Endometrial Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen